Roche Holding (QX) (USOTC:RHHBY)
Historical Stock Chart
1 Month : From Sep 2019 to Oct 2019
By Michael Dabaie
Roche Holding AG's (RHHBY) Genentech said the U.S. Food and Drug Administration approved Rituxan, in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in pediatric patients 2 years of age and older.
GPA and MPA are rare, potentially life-threatening diseases affecting small- and medium-sized blood vessels.
This approval is the first pediatric indication for Rituxan, Genentech said.
Write to Michael Dabaie at email@example.com
(END) Dow Jones Newswires
September 27, 2019 14:17 ET (18:17 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.